{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=69&state=Oregon",
    "query": {
      "state": "Oregon",
      "city": "Portland",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 9379,
    "total_pages": 938,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=70&state=Oregon&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=68&state=Oregon&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:26:56.777Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05647265",
      "title": "Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pleural Biphasic Mesothelioma",
        "Pleural Sarcomatoid Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2024-11-27",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 132,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 74 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05647265"
    },
    {
      "nct_id": "NCT02070692",
      "title": "Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menstruation Disturbances"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "15 Years to 45 Years · Female only"
      },
      "enrollment_count": 56,
      "start_date": "2014-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02070692"
    },
    {
      "nct_id": "NCT07293728",
      "title": "A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension",
        "Preeclampsia"
      ],
      "interventions": [
        {
          "name": "Norethindrone 0.35 MG",
          "type": "DRUG"
        },
        {
          "name": "Drospirenone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2026-07",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07293728"
    },
    {
      "nct_id": "NCT00112411",
      "title": "Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Bronchodilator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": null,
      "start_date": "2005-06-30",
      "completion_date": "2005-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Savannah, Georgia • Louisville, Kentucky + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00112411"
    },
    {
      "nct_id": "NCT03801434",
      "title": "Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BCR-JAK2 Fusion Protein Expression",
        "Blasts 20 Percent or Less of Peripheral Blood White Cells",
        "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells",
        "Blasts More Than 5 Percent of Peripheral Blood White Cells",
        "Blasts Under 20 Percent of Bone Marrow Nucleated Cells",
        "Chronic Eosinophilic Leukemia, Not Otherwise Specified",
        "Eosinophilia",
        "Hepatomegaly",
        "Hypereosinophilic Syndrome",
        "JAK2 Gene Mutation",
        "Splenomegaly",
        "TEL-JAK2 Fusion Protein Expression"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2019-11-15",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801434"
    },
    {
      "nct_id": "NCT04265534",
      "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung",
        "KEAP1 Gene Mutation",
        "NRF2 Gene Mutation",
        "NFE2L2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Telaglenastat",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Folic acid 400 -1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin B12 1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-07-24",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265534"
    },
    {
      "nct_id": "NCT05573464",
      "title": "A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "BGF MDI HFO 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BGF MDI HFA 320/14.4/9.6 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 559,
      "start_date": "2022-09-27",
      "completion_date": "2024-03-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Miami, Florida + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05573464"
    },
    {
      "nct_id": "NCT02564198",
      "title": "A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Solid Tumor",
        "Refractory Tumor",
        "Recurrent Tumor",
        "CNS Malignancies"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-12-11",
      "completion_date": "2019-07-16",
      "has_results": true,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Monrovia, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Monrovia",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02564198"
    },
    {
      "nct_id": "NCT05119712",
      "title": "Terbinafine Treatment of Axial Spondyloarthropathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Ankylosing Spondylitis",
        "Axial Spondyloarthritis",
        "Psoriatic Spondylitis",
        "Spondylitis Secondary to Inflammatory Bowel Disease",
        "Axial Spondyloarthopathy"
      ],
      "interventions": [
        {
          "name": "Terbinafine Tablets",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-03-09",
      "completion_date": "2024-10-15",
      "has_results": false,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119712"
    },
    {
      "nct_id": "NCT01606007",
      "title": "Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with Saxagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1282,
      "start_date": "2012-07",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-19T05:26:56.777Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01606007"
    }
  ]
}